Treatment of PSA only recurrence of prostate cancer after prior local therapy

Current Pharmaceutical Design

Volumn 12, Issue 7, 2006, Pages 785-798

  Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiandrogen Monotherapy; Computed tomography (CT); Dihydrotestosterone (DHT); Prostatectomy; PSA Doubling time (PSA DT); Radiation

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CAPROMAB PENDETIDE IN 111; CYPROTERONE ACETATE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; NILUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANEMIA; BONE SCINTISCANNING; BRACHYTHERAPY; BREAST TENDERNESS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEMATURIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIVER INJURY; LIVER TOXICITY; LOCAL THERAPY; LUNG FIBROSIS; MALE; META ANALYSIS; METASTASIS; MONOTHERAPY; MUSCLE ATROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SYSTEMIC THERAPY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE; VALIDATION PROCESS; BLOOD; PROSTATE TUMOR; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33645323552     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776056092     Document Type: Review

References (157)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Stephenson RA. Population-based prostate cancer trends in the PSA-era: Data from the Surveillance, Epidemiology, and End Results (SEER) Program. Monographs Urol 1998; 19: 1-19.
3. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R, et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002; 132: 213-9.
4. Moul JW. Treatment options for prostate cancer. Part I- stage, grade, PSA, and changes in the 1990's. Am J Manag Care 1998; 4: 1031-6.
5. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632-42.
6. Schulman CC, Altwein JE, Zlotta AR. Treatment options after failure of local curative treatments in prostate cancer: a controversial issue. BJU Int 2000; 86: 1014-22.
7. Moul JW. Prostate biopsy quantitative histology as a staging and prognostic factor. J Urol 2002; 167: (2 Pt 1) 526-527.
8. Ross PL, Scardino PT, Kattan MW. A catalogue of prostate cancer nomograms. J Urol 2001, 165: 1562-1568.
9. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001, 166: 1322-1327.
10. Ravery V. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999; 17: 127.
11. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395.
12. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology 1994; 43: 649.
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591.
14. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999; 162: 293.
15. Amling CL, Bergstralh EJ, Blute ML, Slezak JM. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146.
16. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 2003, 61: 365-369.
17. Witherspoon LR, Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997; 157: 1322.
18. Haese A, Huland E, Graefen M, Hammerer P. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol 1999; 161: 1206.
19. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035.
20. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999; 54: 884.
21. Scher HI. Management of prostate cancer after prostatectomy: Treating the patient, not the PSA. JAMA 1999; 281: 1642.
22. Patel A, Dorey F, Franklin J, DeKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J U Urol 1997; 158: 1441.
23. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clinc Oncol 2002; 20: 4567.
24. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003 Sep 17; 95(18): 1376-83.
25. Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713.
26. Cher ML, Bianco FJ, Lam JS, Davis LP, Grigron DT, Sakr WA. Limited role of radionuclide bone scintigraphy in patients with prostate antigen elevations after radical prostatectomy. J Urol 1998; 160: 1387.
27. Johnstone PAS, Tarman GJ, Riffenburgh R. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 1997; 3: 108.
28. Oh J, Colberg JW, Ornstein DK, Johnston ET, Chan D, Virgo KS, et al. Current followup strategies after radical prostatectomy: A survey of American Urological Association urologists. J. Urol 1999; 161: 520.
29. Kramer S, Gorich J, Gottfried HW, Riska P. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radio 1997; 70: 995.
30. Kahn D, Williams RD, Seldin DW, Libertino JA. Radioimmunoscintigraphy with 111 indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152: 1490.
31. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94: 987.
32. Kahn D, Williams RD, Haseman MK, Reed NL. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Urol 1998; 16: 284.
33. Hinkle GH, Burgers JK, Neal CE, Texter JH. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998; 83: 739.
34. Elgamal AA, Troychak MJ, Murphy GP. Prostascint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998; 37: 261.
35. Quintana JC, Blend MJ. The dual-isotope Prostascint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med 2000; 25: 33.
36. Welsh JS, Yanez MH, Chin BB, Howard SP. Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy. Clin Nucl Med 1999; 24: 983.
37. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (Prostascint) imaging to detect recurrent and metastic prostate cancer. Clin Nucl Med 1998; 23: 672.
38. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, et al. 111 Indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998; 159: 2041.
39. Mohideen N, Flanigan RJ, Dillehay G. Role of ProstaScint scan in the assessment of patients who undergo radiotherapy for biochemical failure after radical prostatectomy for prostate cancer (abstract). J Urol 2002; 167(suppl 4): 174.
40. Sodee DB, Malguria N, Faulhaber P, Resnick MI. Multicenter Prostascint imaging findings in 2154 patients with prostate cancer. The Prostascint Imaging Centers. Urology 2000, 56: 988.
41. Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thame HD, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003 May 1; 21(9): 1715-21.
42. Fang DX, Stock RG, Stone NN, Krynyckyi BR. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (Prostascint) scan for evaluation of patients for salvage brachytherapy. Tech Urol 2000; 6: 146.
43. Foster LS, Jajodia P, Fournier GS, Shinohura K, Carroll P, Narayan P. The value of prostate-specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 1993; 149: 1024.
44. Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 1999; 54: 1044.
45. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989; 142: 326.
46. Svetec D, McCabe K, Peretsman S, Klein E. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol 1998; 159: 1606.
47. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Urol 1999; 17: 1155.
48. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996; 47: 225.
49. Fowler JE Jr, Brooks J, Pandey P, Seaver LE. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995; 153: 1011.
50. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219: 432.
51. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997; 168: 379.
52. Ornstein DK, Oh J, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998; 25: 591.
53. Hoh CK, Seltzer MA, Franklin J, DeKernion JB. Positron emission tomography in urological oncology. J Urol 1998; 159: 347.
54. Sanz G, Robles JE, Gimenez M, Arocena J. Positron emission tomography with 18 fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999; 84: 1028.
55. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162: 1322.
56. Hofer C, Laubenbacher C, Block T, Breul J. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31.
57. DeGrado TR, Coleman RE, Wang S, Baldwin SW. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61: 110.
58. Forman JD, Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Huntingt) 1998; 12: 33.
59. Hudson MA, Catalona WJ. Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol 1990; 143: 1174.
60. Link P, Freiha FS, Stamey TA. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991; 145: 532.
61. Kaplan ID, Bagshaw MA. Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology 1992; 39: 401.
62. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early vs. delayed treatment. J Urol 1994; 151: 1575.
63. Wu JJ, King SC, Montana GS, McKinstry CA. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of senim prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 32: 317.
64. Haab F, Meulemans A, Boccon-Gibod L, Dauge MC. Effect of radiation therapy after radical ptostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 1995; 45: 1022.
65. Schild SE, Buskirk SJ, Wong WW, Halyard MY. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996; 156: 1725.
66. Medini E, Medini I, Reddy PK, Levitt SH. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer 1996; 78: 1254.
67. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996; 47: 232.
68. Forman JD, Meetze K, Pontes E, Wood DP Jr. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997; 158: 1436.
69. Morris MM, Dallow KC, Zeitman AL, Park J, Althausen A, Heney NM. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 731.
70. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159: 173.
71. Garg MK, Tekyi-Mensah S, Bolton S, Velasco J. Impact of post-prostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998; 51: 998.
72. Raymond JF, Vuong M, Russell KJ. Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys 1998; 41: 93.
73. Valicenti RK, Gomella LG, Ismail M, Mullholland SG. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer 1998; 82: 1909.
74. Egawa S, Matsumoto K, Suyama K, Soh S. Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 1999; 53: 148.
75. Vicini FA, Ziaja EL, Kestin LL, Brabbins DS. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999; 54: 111-119.
76. Song DY, Thompson TL, Ramakrishnan V, Harrison R, Bhavsar N, Onaodowan O, et al.: Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002; 60(2): 281-7.
77. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003; 21(3): 483-9.
78. Valicenti RK, Gomella LG, Perez CA. Radiation therapy after radical prostatectomy: a review of the issues and options. Semin Radiat Oncol 2003; 13(2): 130-40.
79. Liauw SL, Webster WS, Pistenmaa DA, Roehrborn CG. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology 2003; 61(6): 1204-10.
80. Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels. J Urol 1995; 153: 104-110.
81. Carson CC 3rd, Zincke H, Utz DC, Cupps RE. Radical prostatectomy after radiotherapy for prostatic cancer. J Urol 1980; 124: 237.
82. Thompson IM, Rounder JB, Spence CR, Rodriguez FR. Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer 1988; 61: 1464.
83. Neerhut GJ, Wheeler T, Cantini M, Scardino PT. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 1988; 140: 544.
84. Link P, Freiha FS. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 1991; 37: 189.
85. Moul JW, Paulson DF. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991; 68: 1265.
86. Ahlering TE, Lieskovsky G, Skinner DG. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol 1992; 147: 900.
87. Pontes JE, Montie J, Klein EJ, Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer 1993; 71: 976.
88. Stein A, Smith RB, deKernion JB. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology 1992; 40: 197.
89. Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995; 154: 1103.
90. Russo P. Salvage radical prostatectomy after radiation therapy and brachytherapy. J Endourol 2000; 14: 385.
91. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998; 159: 950.
92. Gheiler EL, Tefilli MV, Tiguer, R, Grignon D. Predictors for maximal outcome in patients undergoing salvage surgery for radiorecurrent prostate cancer. Urology 1998; 51: 789.
93. Moul JW. Editorial comment to: Garzotto M, Wajsman Z: Androgen deprivation with salvage surgery for radio-recurrent prostate cancer: results at 5-year follow-up. J Urol 1998; 159: 954.
94. Pisters LL. Salvage radical prostatectomy: refinement of an effective procedure. Semin Radiat Oncol 2003; 13(2): 166-74.
95. Vallancien G, Gupta R, Cathelineau X, Baumert H, Rozet F. Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol 2003; 170(5): 1838-40.
96. Brenner PC, Russo P, Wood DP, Morse MJ. Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation. Br J Urol 1995; 75: 44.
97. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001; 165: 1937.
98. Izawa JI, Madsen LT, Scott SM. Long term follow-up of salvage cryotherapy for locally recurrent prostate cancer following radiation therapy (abstract). J Urol 2001; 165: 331a.
99. Katz AE, Rukstalis DB. Introduction. Recent scientific and technological advances have challenged the traditional treatment options for patients with localized prostate cancer. Urology 2002; 60: 1-2
100. Benoit RM, Cohen JK, Miller RJ Jr. Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep 2000 1; 41-47.
101. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003 Oct; 170(4 Pt 1): 1131.
102. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999; 53: 2.
103. Parker CC, Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 1998; 49: 103.
104. Moul JW. A better definition of advanced prostate cancer for today's patients. Contemp Urol 1997; 15-31.
105. Ziada AM, Crawford ED. Advanced prostate cancer. Prost Cancer Prost Dis 1999; 2: 21-6.
106. Cox LE, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-1998.
107. Labrie F, Dupont A, Belanger A, Giquere M. Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in survival. J Steroid Biochem Mol Biol 1985; 23: 833-841.
108. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L. Orchiectomy and nilutamide or placebo as treatment of metastic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77-83.
109. Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R. Prognastic factors in stage D2 prostate cancer, important implications for future trials: Results of a cooperative intergroup study. Semin Oncol 1994; 21: 613-619.
110. Denis LJ, Carnelro de Moura JL Bono A. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC Trial (30853). Urology 1993; 42: 119-129.
111. Schellhammer PF, Sharifi R, Block N. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized multicenter trial. Urology 1997; 50: 330-336.
112. Eisenberger MA, Blumenstein BA, Crawford ED. Bilateral orchiectomy with or without flutamide for metastic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
113. Bertagna C, DeGery A, Huchner M, Francois JP, Zanirato J. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastic prostate cancer: a meta-analysis of seven randomized, double-blind trials (1056 patients). Br J Urol 1994; 73: 396-402.
114. Caubet J, Tosteson TD, Dong EW, Waylon EM, Whiting GW, Ernstoff MS, et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized trials using nonsteroidal antiandrogen. Urology 1997; 49: 71-78.
115. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prost Cancer Prost Dis 1999; 2: 4-8.
116. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials. Lancet 2000; 355: 1491-1498.
117. Crawford DA, Eisenberger MA, McLeod DG. A controlled trial of leuprolide with and without flutamide in prostate cancer. N Engl J Med 1989; 321: 848-853.
118. McLeod DG, Crawford ED, DeAntoni EP. Combined androgen blockade. The gold standard for metastic prostate cancer. Eur Urol 1997; 32: (Suppl 3): 70-77.
119. Denis LJ, Keuppens F, Smith PH. Maximal androgen blockade: Final analysis of EORTC Phase II Trial 30853. Eur Urol 1998; 33: 144-151.
120. Soloway MS, Schellhammer PF, Sharifi R. Bicalutamide and flutamide, each in combination with luteinizing hormone-releasing hormone analogs, in advanced prostate cancer: explanatory analysis of impact of extent of disease by bone scan on outcome. Prostate J 2000; 2: 137-145.
121. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001; 87: 806-13.
122. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 19)7; 79: 235-46.
123. Kirk D. Immediate vs. delayed hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000; 86 (Suppl 3): 220 (Abstr MP6.1.07).
124. Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomized Phase III Eastern Cooperative Oncology Group trial. N Engl J Med 1999; 341: 1781-8.
125. Moul JW, Wu H, Sun L. Early versus delayed hormonal therapy for PSA-only recurrence of prostate cancer after prior radical prostatectomy. J Urol in press, 2004.
126. Schröder FH. Endocrine treatment of prostate cancer-recent developments and the future. Part I: Maximal androgen blockade, early vs. delayed endocrine treatment and side effects. BJU Int 1999; 83: 161-70.
127. Andriole G, Lieber M, Smith J. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995; 45: 491-7.
128. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects. J Urol 1995; 154: 1642-6.
129. Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 1996; 78: 907-10.
130. Ornstein DK, Ganesh RS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48: 901-5.
131. Brufsky A, Fontaine-Rothe P, Berlane K. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-20.
132. Sandhu SS, Matveev VB, Kaisary AV. Finasteride plus flutamide for prostatic carcinoma. Br J Urol 1997; 80: 360.
133. Moul JW, Harding P, Crawford ED, McLeod DG. Combination flutamide and finasteride in PSA-only recurrence after prior local prostate cancer therapy. J Urol 1998; 159 (Suppl): 130 (Abstr 491).
134. Brooks JR, Berman C, Nguyen H. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on growth of the Dunning rat prostatic carcinoma, R-3327. Prostate 1991; 18: 215-7.
135. Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. Five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic carcinoma to macroscopic carcinoma in rats. Cancer 1998; 82: 531-7.
136. Verhelst J, Denis L, Van Vliet P. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994; 41: 525-30.
137. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47: 38-43.
138. Iversen P, Tyrrell CJ, Kaisary AV. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82.
139. Tyrrell CJ, Kaisary AV, Iversen P. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56.
140. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prost Cancer Prost Dis 2001; 4: 196-203.
141. Boccardo F, Rubagotti A, Barichello M. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027-38.
142. Fourcade RO, Chatelain C, Poterre M. An open multicenter randomised study to compare the effect and safety of Casodex (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 1998; 33 (Suppl 1): 88 (Abstr 349).
143. See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer Program. Demography. Urol Oncol 2001; 6: 43-7.
144. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. Bicalutamide ('Casodex') 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429-35.
145. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030-4.
146. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6.
147. Schröder FH. Antiandrogens as monotherapy for prostate cancer. Eur Urol 1998; 34 (Suppl 3): 12-7.
148. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 2250-7.
149. Boccon-Gibod L, Fournier G, Bottet P. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 391-5.
150. Pavone-Macaluso M. Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicenter, randomised study. 23rd Congress of the Societe Internationale d'Urologie (SIU) 1994; Abstr 354.
151. Wirth M, Froehner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999; 36 (Suppl 2): 14-9.
152. Fleshner NE, Trachtenberg J. Sequential androgen blockade: A biological study in the inhibition of prostatic growth. J Urol 1992; 148: 1928-31.
153. Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: Early results. Eur Urol 1993; 24 (Suppl 2): 106-12.
154. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003; 62(5): 872-6.
155. Alexander RL, Kucera GL. Lipid nucleoside conjugates for the treatment of cancer. Curr Pharm Des 2005; 11(9): 1079-89.
156. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004; 10(24): 2981-9.
157. Rege YD, Rangnekar VM. Molecular therapy intervention prospects in prostate cancer. Curr Pharm Des 2004; 10(5): 523-30.